Brief Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 28, 2011; 17(16): 2113-2119
Published online Apr 28, 2011. doi: 10.3748/wjg.v17.i16.2113
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Progression free survival of 23 Taiwanese with metastatic gastrointestinal stromal tumor treated with sunitinib after imatinib failure or intolerance.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Overall survival of 23 Taiwanese with metastatic gastrointestinal stromal tumor treated with sunitinib after imatinib failure or intolerance.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Progression free survival of 18 Taiwanese with metastatic gastrointestinal stromal tumor treated with sunitinib after imatinib failure or intolerance (exon 9 vs exon 11). Median/mean (mo): 3.7/5.6 (exon 9), 8.8/10.2 (exon 11); 95% CI: 0-7.9/2.5-8.6 (exon 9), 2.24-14.4/6.5-14 (exon 11). Log-rank test, P = 0.221.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Overall survival of 18 Taiwanese with metastatic gastrointestinal stromal tumor treated with sunitinib after imatinib failure or intolerance (exon 9 vs exon 11). Median/mean (mo): 13.5/13.7 (exon 9), Not achieved/22.6 (exon 11); 95% CI: 0.9-26.1/9.8-17.7 (exon 9), NA/16.1-29.1 (exon 11). Log-rank test, P = 0.473.